PureTech Health's Vor wins FDA fast-track approval for cancer drug
PureTech Health
156.40p
16:40 23/12/24
1.16%
1.80p
Clinical stage biotherapeutics firm PureTech Health on Friday said its founded entity, Vor Biopharma, had won US fast track approval for its leukaemia treatment.
FTSE 250
20,419.09
17:09 23/12/24
n/a
n/a
FTSE 350
4,471.06
17:09 23/12/24
n/a
n/a
FTSE All-Share
4,428.73
16:44 23/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
20,005.17
17:09 23/12/24
1.24%
244.05
The US Food and Drug Administration granted the designation to VOR33, a hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukaemia.